Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy: The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background —Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes. Methods and Results —Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P =0.01) and LV end-systolic (+19±55 mL [placebo] versus −2±51 mL, P <0.001) volumes after 24 weeks of therapy. LV ejection fraction was unchanged (−0.05% or −0.005) in the placebo group but increased by 2.4% in the metoprolol CR–treated patients ( P =0.001). Patients receiving metoprolol CR had a greater decrease in angiotensin II ( P =0.036) and renin ( P =0.032) levels but an increase in N-terminal atrial natriuretic peptide and brain natriuretic peptide levels ( P <0.01). There were fewer deaths in the group receiving β-blockers (3.4% versus 8.1%), and there was a similar number of patients experiencing the composite outcomes of death or any hospitalization. Conclusions —When added to ACE inhibitors, angiotensin II receptor antagonists, or both, the use of metoprolol CR improves ventricular function, reduces activation of the renin-angiotensin systems, and results in fewer deaths.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Vantrimpont, P., Rouleau, J. L., Wun, C.-C., Ciampi, A., Klein, M., Sussex, B., Arnold, J. M. O., Moyé, L., & Pfeffer, M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00489-5 · Cited by 274
Cited by
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi204 · Cited by 2,260
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
Higgins, S. L., Hummel, J. D., Niazi, I. K., Giudici, M. C., Worley, S. J., Saxon, L. A., Boehmer, J. P., Higginbotham, M. B., De Marco, T., Foster, E., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)01042-8 · Cited by 712
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00006 · Cited by 479
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 474
β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00008 · Cited by 389
Krum, H., Roecker, E. B., Mohacsi, P., Rouleau, J. L., Tendera, M., Coats, A. J. S., Katus, H. A., Fowler, M. B., Packer, M., & for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (2003) · JAMA · doi:10.1001/jama.289.6.712 · Cited by 310
Olsson, L. G., Swedberg, K., Clark, A. L., Witte, K. K., & Cleland, J. G. F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi162 · Cited by 284
Chatterjee, S., Biondi-Zoccai, G., Abbate, A., D'Ascenzo, F., Castagno, D., Van Tassell, B., Mukherjee, D., & Lichstein, E. (2013) · BMJ · doi:10.1136/bmj.f55 · Cited by 279
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment
Eide, I. K., Torjesen, P. A., Drolsum, A., Babovic, A., & Lilledahl, N. P. (2004) · Journal of Hypertension · doi:10.1097/00004872-200411000-00026 · Cited by 265
Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003529 · Cited by 238
Pleger, S. T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R., Schinkel, S., Leuchs, B., Ludwig, J., Qiu, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002097 · Cited by 234
Metadata
- Venue
- Circulation
- Published
- 2000-02
- Volume
- 101
- Issue
- 4
- Pages
- 378-384
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4238915270
- Cited by
- 182
- References
- 2
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.